4/21
11:00 am
life
aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k [Yahoo! Finance]
Low
Report
aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k [Yahoo! Finance]
4/1
08:00 am
life
aTyr Pharma to Participate in April Investor Conferences
Medium
Report
aTyr Pharma to Participate in April Investor Conferences
3/18
02:56 pm
life
aTyr Pharma, Inc. (NASDAQ: LIFE) had its price target lowered by analysts at Royal Bank of Canada from $19.00 to $16.00. They now have an "outperform" rating on the stock.
Low
Report
aTyr Pharma, Inc. (NASDAQ: LIFE) had its price target lowered by analysts at Royal Bank of Canada from $19.00 to $16.00. They now have an "outperform" rating on the stock.
3/16
09:17 am
life
aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
Low
Report
aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
3/15
01:57 pm
life
aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/14
04:21 pm
life
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update [Yahoo! Finance]
High
Report
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update [Yahoo! Finance]
3/14
04:00 pm
life
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
High
Report
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
2/28
08:14 am
life
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results [Yahoo! Finance]
Neutral
Report
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results [Yahoo! Finance]
2/28
08:00 am
life
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Medium
Report
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
2/23
01:46 pm
life
We Think aTyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business Growth [Yahoo! Finance]
Neutral
Report
We Think aTyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business Growth [Yahoo! Finance]
2/21
11:17 am
life
aTyr Pharma, Inc. (NASDAQ: LIFE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
aTyr Pharma, Inc. (NASDAQ: LIFE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
2/21
08:11 am
life
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants [Yahoo! Finance]
Medium
Report
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants [Yahoo! Finance]
2/21
08:00 am
life
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
Medium
Report
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
2/3
07:38 am
life
After losing 23% in the past year, aTyr Pharma, Inc. (NASDAQ:LIFE) institutional owners must be relieved by the recent gain [Yahoo! Finance]
Medium
Report
After losing 23% in the past year, aTyr Pharma, Inc. (NASDAQ:LIFE) institutional owners must be relieved by the recent gain [Yahoo! Finance]
1/29
08:09 am
life
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity [Yahoo! Finance]
Neutral
Report
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity [Yahoo! Finance]
1/29
08:00 am
life
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
Low
Report
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity